Drugs / Leukocyte rich platelet rich plasma
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05737173 | Aug 2020 → Sep 2022 | osteoarthritis, knee | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04384809 | Jan → May 2023 | epicondylitis | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| — | NCT04299802 Comparator | Feb → May 2020 | enthesopathy, tendinitis | Andrews Research & Education Foundation | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukocyte-rich platelet-rich plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737173 ↗ |
| Route | Other | “will be injected in the common extensor tendon” NCT04384809 ↗ |